HNWAG
TVTX icon

High Net Worth Advisory Group’s Travere Therapeutics TVTX Stock Holding History

High Net Worth Advisory Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$25K – 689
2022
Q3 		$25K Hold
1,000
– – 0.01% 422
2022
Q2 		$24K Buy
1,000
+500
+100% +$12.6K 0.01% 426
2022
Q1 		$13K Buy
+500
New +$13.3K ﹤0.01% 503

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

High Net Worth Advisory Group's TVTX Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 1,000 shares — an estimated $25K sold.

High Net Worth Advisory Group first reported a position in TVTX in Q1 2022 and held it in 3 quarters. The position peaked at $25K in Q3 2022. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

  • High Net Worth Advisory Group reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Travere Therapeutics shares in Q4 2022, an estimated $25K.
  • High Net Worth Advisory Group first reported a position in Travere Therapeutics in Q1 2022 and held it in 3 quarters.
  • High Net Worth Advisory Group's Travere Therapeutics position peaked at $25K in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.